Monument's precision medicine approach utilizes proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology matched with appropriately targeted compounds, bringing digital biomarkers to neuroscience drug development in clinical areas of high unmet need. The pipeline includes two core treatments initially targeting cognitive impairment associated with schizophrenia and neuroinflammation, leveraging proprietary digital biomarkers and novel formulations of well-characterized CNS-active small molecules.
Cyborg Score Rationale
Monument demonstrates clear differentiation through its proprietary digital biomarker platform in a large, underserved neuropsychiatric market. Clinical progress and IP protection (US patent granted in April 2026) validate the approach. However, as a private 7-person team at clinical stage with modest funding (~$9-10M raised), execution risk remains.
Top Insights
(April 2026) US patent granted for MT1988, Monument's cognitive impairment schizophrenia candidate, underscoring IP portfolio strength
(March 2026) First patient dosed in clinical trial of MT1988 for Clinical High Risk psychosis, demonstrating clinical advancement
(February 2025) Raised additional £850k from ACF Investors, Wren Capital, o2h Ventures, and Catapult Ventures for pipeline expansion
Leverages partnership with Foundation for the National Institutes of Health (FNIH) for AMP Schizophrenia program, validating research approach
Named Competitors
NGM Biopharmaceuticals — CNS and metabolic disease therapeutics
Genevant — LNP-based therapies for CNS diseases
Lexeo Therapeutics — Gene therapy for CNS disorders
Alto Neuroscience — Precision psychiatry using biomarkers
Recent Developments
(April 2026) US Patent and Trademark Office granted U.S. patent for MT1988, a novel treatment for cognitive impairment associated with schizophrenia
(March 2026) First patient dosed in clinical trial of MT1988 in patients at Clinical High Risk for Psychosis
(February 2025) Raised £850,000 in additional funding led by ACF Investors, Wren Capital, o2h Ventures, and Catapult Ventures
(2024) Presented positive data for MT1980 neuroinflammation candidate at AD/PD conference
Open the full interactive Monument Therapeutics report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.